Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-04-22 DOI:10.1080/14737140.2024.2343801

Olalekan O. Oluwole, Sattva S. Neelapu, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Sally W. Wade, Steve Kanters, Anik R. Patel, Frederick L. Locke

引用次数: 0

Abstract

Studies have compared chimeric antigen receptor (CAR) T-cell therapies and salvage chemotherapy in relapsed/refractory large B-cell lymphoma (LBCL) patients, but further evidence of their relative ...

查看原文本刊更多论文

利用已发表的比较研究对治疗 3L+ R/R LBCL 的 CAR T 细胞疗法进行网络荟萃分析

有研究对复发/难治性大B细胞淋巴瘤（LBCL）患者的嵌合抗原受体（CAR）T细胞疗法和挽救性化疗进行了比较，但有进一步的证据表明这两种疗法的相对疗效 ...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.